CO5261613A1 - INHIBITORS OF PHOSPHODIESTERASA-4 8-SUBSTITUTED ARILQUINOLINES - Google Patents
INHIBITORS OF PHOSPHODIESTERASA-4 8-SUBSTITUTED ARILQUINOLINESInfo
- Publication number
- CO5261613A1 CO5261613A1 CO00096650A CO00096650A CO5261613A1 CO 5261613 A1 CO5261613 A1 CO 5261613A1 CO 00096650 A CO00096650 A CO 00096650A CO 00096650 A CO00096650 A CO 00096650A CO 5261613 A1 CO5261613 A1 CO 5261613A1
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- group
- son
- aryl
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un compuesto representado por la Fórmula (I): <EMI FILE="00096650_1" ID="1" IMF=JPEG >ó una sal farmacéuticamente aceptable de éste, en donde: S1, S2, y S3 son independientemente H, -OH, halógeno, -alquil C1-C6, -NO2, -CN, ó -alcoxi C1-C6, en donde los grupos alquil y alcoxi van opcionalmente sustituidos con 1-5 sustituyentes; en donde cada sustituyente es independientemente un halógeno ó un OH; R1 es H, OH, halógeno, ó un grupo carbonilo, grupo -alquil C1-C6 grupo -cicloalquil C3-C6, grupo -alquenil C1-C6 grupo -alcoxi C1-C6, grupo aril, grupo heteroaril, -CN, grupo -heterociclo-alquil C1-C6, grupo -amino, grupo -alquilamino C1-C6, grupo -(alquil C1-C6)(alquil C1-C6)amino, grupo -alquil C1-C6-(oxi)-alquil C1-C6, grupo -C(O)NH(aril), grupo -C(O)NH(heteroaril), grupo -SOnNH(aril), grupo -SOnNH(heteroaril), grupo -SOnNH(alquil C1-C6), grupo -C(O)N(alquil C0-C6)(alquil C0-C6), grupo -NH-SOn-(alquil C1-C6), grupo -SOn-(alquil C1-C6), grupo -(alquil C1-C6)-O-C(CN)-dialquilamino, ó un grupo -(alquil C1-C6)-SOn-(alquil C1-C6), grupos cada uno de los cuales va opcionalmente sustituido con 1-5 sustituyentes; en donde cada sustituyente es independiente halógeno -OH, -CN, alquil C1-C6, cicloalquil C3-C6, -C(O)(heterociclo-alquil C3-C6), -C(O)-O-(alquil C0-C6), -C(O)-ariloxi, -alcoxi C1-C6, (alquil C0-C6)(alquil C0-C6)amino, cicloalquiloxi, acil, aciloxi, -cicloalquil C3-C6, heterocicloalquil C3-C6, aril, heteroaril, carbonil, carbamoil, ó -SOn-(alquil C1-C6); A es CH, C-éster, ó C-R4;R2 y R3 independientemente son aril, heteroaril, H, halógeno, -CN, -alquil C1-C6, -heterocicloalquil C3-C6, -alcoxi C1-C6 un grupo carbonilo, carbamoil, -C(O)OH, -(alquil C1-C6)-SOn-(alquil C1-C6), -C(O)N(alquil C0-C6)(alquil C0-C6), ó un grupo -alquilamino C1-C6 grupos los cuales van opcionalmente sustituidos con 1-5 sustituyentes, en donde cada sustituyente es independientemente halógeno, -NO2, -C(O)OH, -CN, N-óxido, -OH, ó un grupo sustituyente aril, heteroaril, carbonil, -alquil C1-C6, -SOn-(alquil C1-C6), -SOn-(aril), ariloxi, -heteroariloxi, alcoxi C1-C6, -C(O)-heterocicloalquil C3-C6, ...A compound represented by Formula (I): <EMI FILE = "00096650_1" ID = "1" MFI = JPEG> or a pharmaceutically acceptable salt thereof, wherein: S1, S2, and S3 are independently H, -OH, halogen, -C1-C6 alkyl, -NO2, -CN, or -C1-C6 alkoxy, wherein the alkyl and alkoxy groups are optionally substituted with 1-5 substituents; wherein each substituent is independently a halogen or an OH; R1 is H, OH, halogen, or a carbonyl group, -C1-C6 alkyl group, C3-C6 alkylcyclo group, C1-C6 alkenyl group, C1-C6 alkoxy group, aryl group, heteroaryl group, -CN, group - C1-C6 heterocyclo-alkyl, -amino group, C1-C6 -alkylamino group, group- (C1-C6 alkyl) (C1-C6 alkyl) amino, C1-C6 alkyl- (oxy) -C1-C6 alkyl group, group -C (O) NH (aryl), group -C (O) NH (heteroaryl), group -SOnNH (aryl), group -SOnNH (heteroaryl), group -SOnNH (C1-C6 alkyl), group -C ( O) N (C0-C6 alkyl) (C0-C6 alkyl), group -NH-SOn- (C1-C6 alkyl), group -SOn- (C1-C6 alkyl), group - (C1-C6 alkyl) -OC (CN) -dialkylamino, or a group - (C1-C6 alkyl) -SOn- (C1-C6 alkyl), groups each of which is optionally substituted with 1-5 substituents; wherein each substituent is independently halogen -OH, -CN, C1-C6 alkyl, C3-C6 cycloalkyl, -C (O) (heterocycle-C3-C6 alkyl), -C (O) -O- (C0-C6 alkyl ), -C (O) -aryloxy, -C1-C6 alkoxy, (C0-C6 alkyl) (C0-C6 alkyl) amino, cycloalkyloxy, acyl, acyloxy, -C3-C6 -cycloalkyl, C3-C6 heterocycloalkyl, aryl, heteroaryl , carbonyl, carbamoyl, or -SOn- (C1-C6 alkyl); A is CH, C-ester, or C-R4; R2 and R3 independently are aryl, heteroaryl, H, halogen, -CN, -C1-C6 alkyl, -C3-C6 heterocycloalkyl, a C1-C6 alkoxy a carbonyl group, carbamoyl, -C (O) OH, - (C1-C6 alkyl) -SOn- (C1-C6 alkyl), -C (O) N (C0-C6 alkyl) (C0-C6 alkyl), or a -alkylamino group C1-C6 groups which are optionally substituted with 1-5 substituents, wherein each substituent is independently halogen, -NO2, -C (O) OH, -CN, N-oxide, -OH, or an aryl, heteroaryl substituent group , carbonyl, -C1-C6 alkyl, -SOn- (C1-C6 alkyl), -SOn- (aryl), aryloxy, -heteroaryloxy, C1-C6 alkoxy, -C (O) -heterocycloalkyl C3-C6, ...
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17152299P | 1999-12-22 | 1999-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5261613A1 true CO5261613A1 (en) | 2003-03-31 |
Family
ID=22624050
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO00096650A CO5261613A1 (en) | 1999-12-22 | 2000-12-20 | INHIBITORS OF PHOSPHODIESTERASA-4 8-SUBSTITUTED ARILQUINOLINES |
Country Status (32)
Country | Link |
---|---|
EP (1) | EP1244628A1 (en) |
JP (1) | JP3782011B2 (en) |
KR (1) | KR20020082839A (en) |
CN (1) | CN1221534C (en) |
AR (1) | AR029214A1 (en) |
AU (1) | AU778531B2 (en) |
BG (1) | BG65403B1 (en) |
BR (1) | BR0016651A (en) |
CA (1) | CA2393749C (en) |
CO (1) | CO5261613A1 (en) |
CZ (1) | CZ20022171A3 (en) |
DZ (1) | DZ3244A1 (en) |
EA (1) | EA004747B1 (en) |
EE (1) | EE200200342A (en) |
GE (1) | GEP20053626B (en) |
HK (1) | HK1057560A1 (en) |
HR (1) | HRP20020545A2 (en) |
HU (1) | HUP0203896A3 (en) |
IL (1) | IL150114A0 (en) |
IS (1) | IS6413A (en) |
MX (1) | MXPA02006329A (en) |
MY (1) | MY134008A (en) |
NO (1) | NO20023013L (en) |
NZ (1) | NZ520258A (en) |
PE (1) | PE20010989A1 (en) |
PL (1) | PL355752A1 (en) |
SK (1) | SK8972002A3 (en) |
TW (1) | TWI280240B (en) |
UA (1) | UA74815C2 (en) |
WO (1) | WO2001046151A1 (en) |
YU (1) | YU47102A (en) |
ZA (1) | ZA200204862B (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7776315B2 (en) | 2000-10-31 | 2010-08-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and additional active ingredients |
DE10110772A1 (en) * | 2001-03-07 | 2002-09-12 | Boehringer Ingelheim Pharma | New drug compositions based on anticholinergics and PDE-IV inhibitors |
EA005864B1 (en) * | 2000-12-20 | 2005-06-30 | Мерк Энд Ко., Инк. | Process for making substituted 8-arylquinolinium benzenesulfonate |
US6740666B2 (en) * | 2000-12-20 | 2004-05-25 | Merck & Co., Inc. | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
DE60204463T2 (en) | 2001-06-27 | 2006-05-18 | Merck Frosst Canada & Co, Kirkland | Substituted 8-arylquinolines as PDE4 inhibitors |
US7009055B2 (en) * | 2001-07-24 | 2006-03-07 | Merck & Co., Inc. | Preparation of Sulfonyl quinoline |
PL205927B1 (en) * | 2001-09-19 | 2010-06-30 | Nycomed Gmbh | Combination of a pde inhibitor and a leukotriene receptor antagonist |
ATE432261T1 (en) * | 2002-03-18 | 2009-06-15 | Merck Frosst Canada Ltd | PDE4 INHIBITORS WITH HETEROBIDGE SUBSTITUTED 8-ARYLCINOLINE |
NZ542407A (en) * | 2003-03-05 | 2008-08-29 | Celgene Corp | Diphenylethylene compounds and uses thereof |
JP2007530594A (en) * | 2004-03-25 | 2007-11-01 | シンタ ファーマシューティカルズ コーポレーション | Acrylonitrile derivatives for use in inflammation and immunity related applications |
JP2008545389A (en) * | 2005-05-19 | 2008-12-18 | シナージェンズ バイオサイエンス リミティド | Methods and compositions for assessment of lung function and lung injury |
RS53461B (en) | 2006-07-05 | 2014-12-31 | Takeda Gmbh | Combination of hmg-coa reductase inhibitors atorvastatin or simvastatin with a phosphodiesterase 4 inhibitor, such as roflumilast for the treatment of inflammatory pulmonary diseases |
MX2009000148A (en) * | 2006-07-07 | 2009-10-26 | Kalypsys Inc | Bicyclic heteroaryl inhibitors of pde4. |
US20080103105A1 (en) * | 2006-09-22 | 2008-05-01 | Braincells, Inc. | HMG CoA REDUCTASE MEDIATED MODULATION OF NEUROGENESIS |
WO2008099210A2 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
WO2009128057A2 (en) | 2008-04-18 | 2009-10-22 | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al | Psycho-pharmaceuticals |
EP2533780B1 (en) | 2010-02-12 | 2017-08-23 | AskAt Inc. | 5-ht4 receptor agonists for the treatment of dementia |
EP2741777B1 (en) | 2011-08-12 | 2017-01-18 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
US20140328893A1 (en) | 2011-10-11 | 2014-11-06 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Nutlin compounds for use in the treatment of pulmonary hypertension |
JP2020532551A (en) * | 2017-09-03 | 2020-11-12 | アンジオン バイオメディカ コーポレーション | Vinyl heterocycle as a Rho-related coiled coil kinase (ROCK) inhibitor |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9226830D0 (en) * | 1992-12-23 | 1993-02-17 | Celltech Ltd | Chemical compounds |
US5455252A (en) * | 1993-03-31 | 1995-10-03 | Syntex (U.S.A.) Inc. | Optionally substituted 6,8-quinolines |
US6245774B1 (en) * | 1994-06-21 | 2001-06-12 | Celltech Therapeutics Limited | Tri-substituted phenyl or pyridine derivatives |
JPH11209350A (en) * | 1998-01-26 | 1999-08-03 | Eisai Co Ltd | Nitrogen-containing heterocyclic derivative and medicine containing the same |
-
2000
- 2000-12-19 MY MYPI20005965A patent/MY134008A/en unknown
- 2000-12-20 AU AU23362/01A patent/AU778531B2/en not_active Ceased
- 2000-12-20 CO CO00096650A patent/CO5261613A1/en not_active Application Discontinuation
- 2000-12-20 UA UA2002076108A patent/UA74815C2/en unknown
- 2000-12-20 BR BR0016651-0A patent/BR0016651A/en not_active IP Right Cessation
- 2000-12-20 CN CNB00818951XA patent/CN1221534C/en not_active Expired - Fee Related
- 2000-12-20 DZ DZ003244A patent/DZ3244A1/en active
- 2000-12-20 EA EA200200702A patent/EA004747B1/en not_active IP Right Cessation
- 2000-12-20 GE GE4903A patent/GEP20053626B/en unknown
- 2000-12-20 PL PL00355752A patent/PL355752A1/en not_active IP Right Cessation
- 2000-12-20 EP EP00986937A patent/EP1244628A1/en not_active Withdrawn
- 2000-12-20 IL IL15011400A patent/IL150114A0/en unknown
- 2000-12-20 SK SK897-2002A patent/SK8972002A3/en not_active Application Discontinuation
- 2000-12-20 JP JP2001547062A patent/JP3782011B2/en not_active Expired - Fee Related
- 2000-12-20 KR KR1020027008079A patent/KR20020082839A/en not_active Application Discontinuation
- 2000-12-20 CZ CZ20022171A patent/CZ20022171A3/en unknown
- 2000-12-20 EE EEP200200342A patent/EE200200342A/en unknown
- 2000-12-20 MX MXPA02006329A patent/MXPA02006329A/en not_active Application Discontinuation
- 2000-12-20 YU YU47102A patent/YU47102A/en unknown
- 2000-12-20 HU HU0203896A patent/HUP0203896A3/en unknown
- 2000-12-20 NZ NZ520258A patent/NZ520258A/en unknown
- 2000-12-20 WO PCT/CA2000/001559 patent/WO2001046151A1/en active IP Right Grant
- 2000-12-20 CA CA002393749A patent/CA2393749C/en not_active Expired - Fee Related
- 2000-12-21 TW TW089127506A patent/TWI280240B/en not_active IP Right Cessation
- 2000-12-21 AR ARP000106867A patent/AR029214A1/en not_active Application Discontinuation
- 2000-12-22 PE PE2000001396A patent/PE20010989A1/en not_active Application Discontinuation
-
2002
- 2002-06-11 IS IS6413A patent/IS6413A/en unknown
- 2002-06-18 ZA ZA200204862A patent/ZA200204862B/en unknown
- 2002-06-19 BG BG106840A patent/BG65403B1/en unknown
- 2002-06-21 HR HR20020545A patent/HRP20020545A2/en not_active Application Discontinuation
- 2002-06-21 NO NO20023013A patent/NO20023013L/en unknown
-
2004
- 2004-01-26 HK HK04100511A patent/HK1057560A1/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5261613A1 (en) | INHIBITORS OF PHOSPHODIESTERASA-4 8-SUBSTITUTED ARILQUINOLINES | |
PL373672A1 (en) | Acridone inhibitors of impdh enzyme | |
CO5261497A1 (en) | RANGE-HYDROXI-2- (FLUOROALQUILAMINO-CARBONIL) -1-PIPERAZINO PENTANAMIDAS AND ITS USES | |
AR044749A1 (en) | INHIBITOR OF THE RNA DEPENDENT RNA POLYMERASE OF THE HEPATITIS C VIRUS AND COMPOSITIONS AND TREATMENTS USING | |
CO4910135A1 (en) | CETOLID DERIVATIVES 6-0 SUBSTITUTED FOR ERYTHROMYCIN THAT HAVE BACTERIAL ACTIVITY | |
CO5080782A1 (en) | HETEROCICLICAL COMPOUNDS AS INHIBITORS OF ROTAMASA ENZYMES | |
RU2004137480A (en) | Hepatitis C Virus Inhibitors | |
TW359670B (en) | Process for producing quinazolin-4-one derivatives | |
CO5251410A1 (en) | NITRILE DERIVATIVES AS INHIBITORS OF CAPTESIN K | |
CA2615022A1 (en) | Hcv ns3 protease inhibitors | |
RU2007132260A (en) | SYNTHESIS OF ARILPYRROLIDONES | |
TW200510338A (en) | 3-substituted-4-pyrimidone derivatives | |
EA200300763A1 (en) | PYRIDINE INHIBITORS OF MATRIX METALLOPROTEINASES | |
CO5170518A1 (en) | N- (BENZOCICLOALQUILO) COMPOUNDS DERIVED FROM AMINO ARALIFATICOS | |
CO5261616A1 (en) | NON-PEPTIDIC INHIBITORS OF THE CELLULAR UNION DEPENDENTS OF VLA-4 USEFUL IN THE TREATMENT OF INFLAMMATORY, AUTOIMMUNE AND RESPIRATORY DISEASES | |
TW200640885A (en) | Novel haoalkanesulfonylaniline derivatives, weed killer and the use methods thereof | |
CA2615896A1 (en) | Macrocyclic peptides as hcv ns3 protease inhibitors | |
WO2000009483A3 (en) | Process and intermediates for production of donepezil and related compounds | |
CO4900066A1 (en) | TETRAHYDROKINOLINE DERIVATIVES | |
ES2122258T3 (en) | 4-AZAESTEROIDS 15 SUBSTITUTED. | |
WO1991008775A3 (en) | Maleic anhydride derivatives used as conjugation agents of anti-tumor agents on desired carriers | |
CO5140112A1 (en) | BENZIMIDAZOL COMPOUNDS THAT ARE VITRONECTINE RECEPTOR ANTAGONISTS | |
EP1465488A4 (en) | Arylamines as inhibitors of chemokine binding to us28 | |
EP1491533A3 (en) | Quinoline-and naphthalenecarboxamides, pharmaceutical compositions thereof and their use as calpain inhibitors | |
CO5170520A1 (en) | DERIVATIVES OF 4- (REPLACED PHENYL) -2-PIPERAZINIL-PIRIMIDIN- (3,5-BISTRIFLUORO-METIL-BENCIL) - METIL-AMIDA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |